This is highlighted by the findings that acetylcholinesterase inhibitors, α7 nAChR partial agonists, AMPA (GluA)-positive allosteric modulators, GABAA α2/α3 partial agonists, and DAT and NET inhibitors reverse cognitive dysfunction in a putatively schizophrenia-relevant rodent model as determined by the novel object recognition task, yet do not improve cognition, as determined by a range of rating scales, in clinical trials of schizophrenia patients (Table 1) [27, 63–75]. This evidence concerns the gene SLC6A3 and schizophrenia.